GlaxoSmithKline PLC expects its Flonase SensimistAllergy Relief (fluticasone furoate/27.5mcg spray) to build upon the success of the original Flonase OTC line and help counter recent private label competitive activity in the intranasal corticosteroid category.
“We’re very optimistic that we can follow the huge success of Flonase,” said CEO Andrew Witty on Feb
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?